Adequate protein intake is essential for preserving lean muscle mass, maintaining metabolic health, and optimising treatment outcomes
The results showed significant discontinuation rates: 26.2% at three months, 30.8% at six months, and 36.5% at 12 months
Current consensus is that GLP-1 treatment benefits outweigh the risk of EWDR: the drugs reduce the risk of further microvascular damage from poor glycemic control and reduce the chance of death from cardiovascular disease, while the impact on DR is short-lived and can be treated
Do not let the fact you are on a GLP keep you from getting medical help if you need it
Linagliptin is the exception, with 10,000 patients, exposed for up to 2 years) of the sitagliptin and vildagliptin clinical trials have been published, showing no increased risk for urinary tract or respiratory infections or headache (and indeed, no increased risk of any other adverse effect) with the DPP-4 inhibitors compared to placebo or comparator [95,96]